CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. Our team has over 20 years’ experience in oncology and molecular cell biology and are using our expertise and experience in these areas to develop novel innovative treatments that will enhance the effectiveness of standard-of-care therapies in oncology and other inflammatory conditions.
CV6 Therapeutics is dedicated to the development of novel innovative therapeutics to enhance the effectiveness of the most widely used, standard-of-care therapies and to improve the lives of patients with cancer and inflammatory diseases.
Belfast, U.K. – May 17, 2018 – CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of three new members to their Scientific Advisory Board. Paul Workman, PhD, Chief Executive and President of The Institute of Cancer Research (ICR), London, […]Find Out More